O.T. Brustugun

2.5k total citations
5 papers, 72 citations indexed

About

O.T. Brustugun is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, O.T. Brustugun has authored 5 papers receiving a total of 72 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 1 paper in Surgery. Recurrent topics in O.T. Brustugun's work include Lung Cancer Treatments and Mutations (3 papers), Pancreatic and Hepatic Oncology Research (1 paper) and Sarcoma Diagnosis and Treatment (1 paper). O.T. Brustugun is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), Pancreatic and Hepatic Oncology Research (1 paper) and Sarcoma Diagnosis and Treatment (1 paper). O.T. Brustugun collaborates with scholars based in Norway, Australia and Singapore. O.T. Brustugun's co-authors include Åslaug Helland, Mette Sprauten, John K. Field, Roman K. Thomas, Andreas Hallqvist, Thomas Zander, Gavin Wright, Frauke Leenders, Rolf Lewensohn and Jan Nyman and has published in prestigious journals such as Cancer Research, International Journal of Cancer and Radiotherapy and Oncology.

In The Last Decade

O.T. Brustugun

5 papers receiving 71 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
O.T. Brustugun Norway	5	48	45	11	11	9	5	72
Susanna Y. Cheng Canada	5	49 1.0×	36 0.8×	20 1.8×	4 0.4×	12 1.3×	15	92
Sophia J. Luo United States	5	66 1.4×	43 1.0×	10 0.9×	7 0.6×	2 0.2×	10	94
Audrey Rabeau France	6	36 0.8×	64 1.4×	18 1.6×	20 1.8×	1 0.1×	16	96
Virginia Wolstenholme United Kingdom	4	34 0.7×	31 0.7×	10 0.9×	3 0.3×	11 1.2×	6	54
Emmanuelle Jacquet France	6	27 0.6×	42 0.9×	6 0.5×	12 1.1×		13	83
A. Radkowski Poland	5	31 0.6×	22 0.5×	17 1.5×	3 0.3×	10 1.1×	11	70
J.J. Lee United States	4	35 0.7×	32 0.7×	5 0.5×	4 0.4×	7 0.8×	11	57
Juan Pablo Sade Argentina	6	56 1.2×	32 0.7×	14 1.3×	5 0.5×	2 0.2×	16	100
Isaura Parente Lamelas Spain	6	71 1.5×	31 0.7×	9 0.8×	5 0.5×	1 0.1×	11	89
Angela Stefania Ribecco Italy	7	25 0.5×	59 1.3×	15 1.4×	8 0.7×		13	91

Countries citing papers authored by O.T. Brustugun

Since Specialization

Citations

This map shows the geographic impact of O.T. Brustugun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O.T. Brustugun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O.T. Brustugun more than expected).

Fields of papers citing papers by O.T. Brustugun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O.T. Brustugun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O.T. Brustugun. The network helps show where O.T. Brustugun may publish in the future.

Co-authorship network of co-authors of O.T. Brustugun

This figure shows the co-authorship network connecting the top 25 collaborators of O.T. Brustugun. A scholar is included among the top collaborators of O.T. Brustugun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O.T. Brustugun. O.T. Brustugun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Morabito, Alessandro, Isamu Okamoto, O.T. Brustugun, et al.. (2025). 1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD. Journal of Thoracic Oncology. 20(3). S2–S4. 5 indexed citations

2.

Helland, Åslaug, O.T. Brustugun, Sigve Nakken, et al.. (2017). High number of kinome‐mutations in non‐small cell lung cancer is associated with reduced immune response and poor relapse‐free survival. International Journal of Cancer. 141(1). 184–190. 6 indexed citations

3.

Brustugun, O.T., Mette Sprauten, & Åslaug Helland. (2016). Real-world data on nivolumab treatment of non-small cell lung cancer. Acta Oncologica. 56(3). 438–440. 35 indexed citations

4.

Nyman, Jan, Andreas Hallqvist, O.T. Brustugun, et al.. (2014). OC-0565: SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiotherapy and Oncology. 111. S221–S221. 14 indexed citations

5.

Fernandez‐Cuesta, Lynnette, Martin Peifer, Xin Lü, et al.. (2014). Abstract 1531: Cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets. Cancer Research. 74(19_Supplement). 1531–1531. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact